Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 10 de 10
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Rheumatology (Oxford) ; 49(4): 662-70, 2010 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-20097906

RESUMEN

OBJECTIVE: B cells lacking RP105 produce autoantibodies in patients with SLE. Expression of B-cell activating factor (BAFF) binding receptors (BBRs) and survival of RP105(-) B cells from SLE patients were examined. METHODS: Detection of difference of gene expression between RP105(-) and RP105(+) B cells was done by DNA microarrays. Surface expression was confirmed by flow cytometry. The contribution of BAFF, a proliferation-inducing ligand (APRIL) and monomers/trimers of sCD40L to survival of RP105(-) and RP105(+) B cells was examined. RESULTS: Gene expression of B-cell maturation antigen (BCMA) was different among BBRs in RP105(-) and RP105(+) B cells in SLE. Preferential expression of BCMA on RP105(-) B cells was confirmed compared with RP105(+) B cells by flow cytometry, although BAFF receptor (BAFF-R) expression on RP105(-) B cells was significantly lower. Additionally, relative ratios of BCMA/BAFF-R expression on RP105(-) B cells were increased significantly in SLE patients compared with normal subjects. Stimulation by sCD40L decreased the number of surviving RP105(-) and RP105(+) B cells in vitro. RP105(+) B cells were not rescued from sCD40L-induced cell death by BAFF and/or APRIL. In contrast, either BAFF or APRIL maintained the survival of RP105(-) B cells due to avoidance of cell death. Activated RP105(-) B cells reduced BAFF-R and increased BCMA levels. CONCLUSIONS: RP105(-) B cells from SLE patients showed more preferential expression of BCMA compared with BAFF-R than normal subjects, and were possibly regulated by BAFF/APRIL. Our results provide a new insight of BCMA and their ligands in B cells from SLE patients.


Asunto(s)
Autoanticuerpos/inmunología , Receptor del Factor Activador de Células B/inmunología , Antígeno de Maduración de Linfocitos B/inmunología , Lupus Eritematoso Sistémico/inmunología , Adolescente , Adulto , Anciano , Receptor del Factor Activador de Células B/genética , Antígeno de Maduración de Linfocitos B/genética , Estudios de Casos y Controles , Femenino , Citometría de Flujo , Humanos , Lupus Eritematoso Sistémico/genética , Masculino , Persona de Mediana Edad , Reacción en Cadena de la Polimerasa , Adulto Joven
2.
Mod Rheumatol ; 19(2): 173-9, 2009.
Artículo en Inglés | MEDLINE | ID: mdl-19067109

RESUMEN

To assess the effects of disease activity of systemic lupus erythematosus (SLE) and high-dose corticosteroids on endothelial injuries, the significance of soluble endothelial cell protein C receptor (sEPCR) and soluble thrombomodulin (sTM) was analyzed. Serum levels of sEPCR and sTM were measured by enzyme-linked immunosorbent assay (ELISA) cross-sectionally in 97 SLE patients, 49 patients with other rheumatic diseases and 22 normal subjects. The changes in these levels upon corticosteroid treatment were also analyzed in 41 patients. The levels of sEPCR and sTM were both higher in SLE and other rheumatic disease patients than in normal subjects. When low-dose corticosteroids were used, both the level of sEPCR and the ratio of positive tests for sEPCR were significantly higher in active SLE patients than in inactive patients [median 2.30 ng/ml (range 0.00-147.10 ng/ml) vs 0.00 ng/ml (0.00-58.90 ng/ml) and 53.5 vs 13.0%, respectively] (P < 0.005). Moreover, the ratio of positive tests for sEPCR was higher after corticosteroid treatment in 9 of 19 (47.3%) SLE patients compared to other rheumatic diseases (3/22; 13.6%). Although the mean level of sTM was significantly higher in active SLE patients than in inactive patients, the ratio of positive tests for sTM was not affected by disease activity or corticosteroids. In conclusion, the positive test for sEPCR is a more sensitive biomarker than that for sTM in reflecting endothelial injuries caused by active disease and often by corticosteroids in SLE.


Asunto(s)
Corticoesteroides/farmacología , Antígenos CD/sangre , Lupus Eritematoso Sistémico/sangre , Receptores de Superficie Celular/sangre , Corticoesteroides/uso terapéutico , Adulto , Progresión de la Enfermedad , Receptor de Proteína C Endotelial , Femenino , Humanos , Lupus Eritematoso Sistémico/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Trombomodulina/sangre
3.
Scand J Infect Dis ; 39(6-7): 577-83, 2007.
Artículo en Inglés | MEDLINE | ID: mdl-17577821

RESUMEN

Toll-like receptor 4 (TLR4) recognizes lipopolysaccharide (LPS) and other exogenous and endogenous molecules, and is thought to contribute to defense mechanisms against infections. Our objective was to elucidate the clinical significance of TLR4 in acute infectious diseases by analyzing its sequential expression on CD14+ monocytes. Peripheral blood samples were obtained from 36 patients with acute infectious diseases on admission and after treatment within certain intervals. The TLR4 expression on CD14+ monocytes was analyzed using flow cytometry and was presented as a mean fluorescence intensity (MFI). TLR4 expression during the acute phase of infection was highly enhanced compared to that of normal subjects (MFI: 22.1 vs 8.5). TLR4 expression was promptly reduced to normal levels in parallel with the disease improvement. In patients who died despite treatment, the enhancement of TLR4 expression during the acute phase was less prominent compared to those who survived (MFI: 14.6 vs 23.5) and its sequential change was also subtle. These results indicate that monocytes respond to acute infections by the induction of TLR4 expression and that a poor response may be associated with a poor prognosis.


Asunto(s)
Enfermedades Transmisibles/inmunología , Receptores de Lipopolisacáridos/biosíntesis , Monocitos/inmunología , Receptor Toll-Like 4/biosíntesis , Enfermedad Aguda , Adulto , Anciano , Anciano de 80 o más Años , Enfermedades Transmisibles/microbiología , Enfermedades Transmisibles/mortalidad , Femenino , Humanos , Receptores de Lipopolisacáridos/inmunología , Lipopolisacáridos/inmunología , Masculino , Persona de Mediana Edad , Monocitos/metabolismo , Pronóstico , Receptor Toll-Like 4/inmunología
4.
Kansenshogaku Zasshi ; 81(3): 305-8, 2007 May.
Artículo en Japonés | MEDLINE | ID: mdl-17564121

RESUMEN

A 21-year-old woman admitted for a low-grade fever, dry cough, polyarthralgia, and general fatigue was found to have elevateal accustomed to eating raw meat and cattle liver peripheral blood eosinophil counts and serum IgE. Chest X-ray imaging and computed tomography (CT) showed multiple small nodules in both lung fields. A multiple dot-ELISA assay of her serum showed that she had visceral larva migrans caused by Ascaris suum or Toxocara canis. Following treatment with albendazole, she developed myelopathy and was again admitted. A cerebrospinal fluid examination showed increased eosionophils and significant antibody elevation against T. canis. Her disease was considered to have entered the central nervous system, one of the target organs of visceral larva migrans. She was successfully treated with dietylcarbamazine and has shown no reccurrence. This case showed the different manifestations of visceral larva migrans and the rising incidence of this disease in Japan raises concerns about associated of diet.


Asunto(s)
Larva Migrans Visceral/complicaciones , Toxocara canis , Adulto , Animales , Femenino , Humanos
5.
Mod Rheumatol ; 16(6): 364-71, 2006.
Artículo en Inglés | MEDLINE | ID: mdl-17164998

RESUMEN

We investigated the effect of hepatocyte growth factor (HGF) on collagen metabolism in cultured fibroblasts from scleroderma (SSc) patients and discussed the possible mechanism of its effect. Synthesis of matrix metalloproteinase-1 (MMP-1) and collagen and mRNA levels of various cytokines were examined by enzyme-linked immunosorbent assay and real-time polymerase chain reaction, respectively. Hepatocyte growth factor enhanced MMP-1 production and mRNA levels of MMP-1 and Ets-1 (a transcriptional factor of MMPs). In addition, HGF suppressed collagen synthesis and mRNA levels of procollagenalpha1(I) and connective tissue growth factor (CTGF) in SSc fibroblasts. Expression of transforming growth factor (TGF)-beta1 was not inhibited significantly in SSc or control fibroblasts. Hepatocyte growth factor also increased interferon (IFN)-gamma mRNA significantly in SSc and control fibroblasts. Addition of anti-HGF antibody neutralized these effects of HGF on MMP-1 and collagen synthesis. The results suggest that HGF can suppress collagen accumulation in SSc fibroblasts by increasing MMP-1 levels possibly via activation of Ets-1 and also by decreasing collagen synthesis, which may be partly related to inhibition of CTGF, and increasing IFN-gamma levels rather than the effect on TGF-beta1. The present study indicates that HGF may be a promising therapeutic agent for this intractable disease.


Asunto(s)
Fibroblastos/patología , Factor de Crecimiento de Hepatocito/farmacología , Esclerodermia Difusa/patología , Esclerodermia Limitada/patología , Piel/patología , Anticuerpos Bloqueadores/farmacología , Células Cultivadas , Colágeno/metabolismo , Colágeno Tipo I/genética , Colágeno Tipo I/metabolismo , Cadena alfa 1 del Colágeno Tipo I , Factor de Crecimiento del Tejido Conjuntivo , Citocinas/genética , Citocinas/metabolismo , Relación Dosis-Respuesta a Droga , Ensayo de Inmunoadsorción Enzimática , Femenino , Fibroblastos/efectos de los fármacos , Factor de Crecimiento de Hepatocito/inmunología , Humanos , Proteínas Inmediatas-Precoces/genética , Proteínas Inmediatas-Precoces/metabolismo , Péptidos y Proteínas de Señalización Intercelular/genética , Péptidos y Proteínas de Señalización Intercelular/metabolismo , Masculino , Metaloproteinasa 1 de la Matriz/metabolismo , Proteína Proto-Oncogénica c-ets-1/genética , Proteína Proto-Oncogénica c-ets-1/metabolismo , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
6.
Clin Immunol ; 120(2): 179-88, 2006 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-16616645

RESUMEN

Inducible costimulator (ICOS) is a costimulatory molecule expressed in activated T cells and plays an important role in T-cell-dependent immune responses. We investigated the role of ICOS in the development of autoimmune diseases in MRL/Mpj-lpr/lpr (MRL/lpr) mice. ICOS was expressed on CD4(+) T cells from adult MRL/lpr mice. ICOS-deficient MRL/lpr mice showed mild lymphoadenopathy and a decreased memory type CD4(+) T cells in the spleen. The anti-dsDNA antibody levels were decreased. CD4(+) T cells from ICOS-deficient MRL/lpr mice showed less of a bias to Th1 and an enhanced production of IL-4 in response to anti-CD3 antibody in comparison to those from wild-type MRL/lpr mice. Although ICOS-deficiency abrogated renal vasculitis completely, the severity of glomerulonephritis was not altered. ICOS is considered to play a role in CD4(+) T cell activation, autoantibody production, and renal vasculitis. However, it is not essentially required in the development of glomerulonephritis.


Asunto(s)
Antígenos de Diferenciación de Linfocitos T/genética , Antígenos de Diferenciación de Linfocitos T/fisiología , Lupus Vulgar/etiología , Animales , Citocinas/biosíntesis , Citocinas/sangre , Modelos Animales de Enfermedad , Femenino , Glomerulonefritis/complicaciones , Glomerulonefritis/mortalidad , Inmunoglobulinas/sangre , Proteína Coestimuladora de Linfocitos T Inducibles , Riñón/patología , Lupus Vulgar/complicaciones , Lupus Vulgar/inmunología , Enfermedades Linfáticas/inmunología , Ratones , Ratones Endogámicos MRL lpr , Ratones Noqueados , Bazo/citología , Bazo/inmunología , Esplenomegalia/inmunología , Linfocitos T/inmunología
7.
J Rheumatol ; 32(3): 562-4, 2005 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-15742454

RESUMEN

B cells lacking RP105 molecule, a member of the Toll-like receptor family, were increased in the peripheral blood of 2 patients with antinuclear antibody (ANA) negative systemic lupus erythematosus (SLE). The increased proportion of RP105-lacking B cells was associated with disease activity in patients with ANA-negative SLE. When there are no significant serological markers for SLE, analysis of expression of RP105 may be helpful in evaluation of activity in ANA-negative SLE. We describe a new approach, using phenotyping of B cells, to evaluate activity of ANA-negative SLE.


Asunto(s)
Anticuerpos Antinucleares/inmunología , Antígenos CD/inmunología , Linfocitos B/metabolismo , Lupus Eritematoso Sistémico/inmunología , Adulto , Anticuerpos Antinucleares/sangre , Antígenos CD/sangre , Biomarcadores , Encéfalo/inmunología , Encéfalo/patología , Humanos , Lupus Eritematoso Sistémico/sangre , Masculino
8.
Arthritis Rheum ; 48(11): 3280-90, 2003 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-14613294

RESUMEN

OBJECTIVE: Platelet endothelial cell adhesion molecule 1 (PECAM-1; CD31) is a member of the immunoglobulin superfamily that is expressed in platelets, leukocytes, and endothelial cells. PECAM-1 has been shown to play a role in transendothelial migration of leukocytes and contains immunoreceptor tyrosine-based inhibitory motifs in its cytoplasmic tail and inhibits cellular responses. We examined the role of PECAM-1 in the development of collagen-induced arthritis (CIA). METHODS: CIA was induced in PECAM-1-deficient DBA/1 mice. The incidence of arthritis and the arthritis index were examined. Anti-type II collagen (anti-CII) antibody levels and interferon-gamma (IFNgamma) production by lymph node cells and spleen cells were determined. Lymphocytes from arthritic PECAM-1-deficient and wild-type mice were labeled with dye, transferred to arthritic PECAM-1(+/-) mice, and cell migration to inflamed joints was examined. RESULTS: PECAM-1-deficient mice showed accelerated onset of arthritis and increased severity only during the early phase. Anti-CII antibody levels were also increased during the early phase. IFNgamma production by lymph node cells and spleen cells from PECAM-1-deficient mice in response to CII was higher than that in wild-type mice. Lymphocytes from arthritic PECAM-1-deficient mice showed accelerated migration to inflamed joints, but not lymph nodes or spleen. The development of anti-CII antibody-induced arthritis was similar in PECAM-1-deficient and wild-type mice. CONCLUSION: These results indicate that PECAM-1 negatively regulates humoral and cell-mediated immune responses and lymphocyte migration into joints and, consequently, the development of CIA. In addition, the role of PECAM-1 in the transendothelial migration of leukocytes appears to be redundant in this model.


Asunto(s)
Artritis Experimental/metabolismo , Colágeno Tipo II , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/biosíntesis , Traslado Adoptivo , Animales , Artritis Experimental/inmunología , Artritis Experimental/patología , Autoanticuerpos/sangre , Movimiento Celular , Colágeno Tipo II/inmunología , Colágeno Tipo II/farmacología , Modelos Animales de Enfermedad , Miembro Posterior/patología , Inmunoglobulina G/sangre , Interferón gamma/metabolismo , Articulaciones/patología , Ganglios Linfáticos/metabolismo , Activación de Linfocitos/inmunología , Ratones , Ratones Endogámicos DBA , Ratones Noqueados , Molécula-1 de Adhesión Celular Endotelial de Plaqueta/genética , Bazo/citología , Bazo/metabolismo , Linfocitos T/inmunología
9.
Gan To Kagaku Ryoho ; 30(3): 371-5, 2003 Mar.
Artículo en Japonés | MEDLINE | ID: mdl-12669396

RESUMEN

A multicenter cooperative study of docetaxel (60 mg/m2) combined with cisplatin (60 mg/m2) was performed in stage III and IV patients with inoperable non-small cell lung cancer from March 1998 to September 1999. Of 37 patients enrolled, 36 patients were eligible. One patient obtained a complete response (CR) and nine patients had a partial response (PR). The overall response rate in 36 patients was 28.6%. The median survival time was 360 days. The response rates of stage III and stage IV patients were 36.8% and 18.7%, respectively. The median survival times of stage III and stage IV patients were 502 days and 286 days, respectively. The major toxicities were grade 3 leukopenia (16.2%), grade 3 neutropenia (32.4%), and grade 4 neutropenia (10.8%).


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Carcinoma de Pulmón de Células no Pequeñas/tratamiento farmacológico , Neoplasias Pulmonares/tratamiento farmacológico , Paclitaxel/análogos & derivados , Taxoides , Adulto , Anciano , Carcinoma de Pulmón de Células no Pequeñas/mortalidad , Cisplatino/administración & dosificación , Docetaxel , Esquema de Medicación , Femenino , Humanos , Neoplasias Pulmonares/mortalidad , Masculino , Persona de Mediana Edad , Paclitaxel/administración & dosificación , Tasa de Supervivencia
10.
Ryumachi ; 42(6): 872-8, 2002 Dec.
Artículo en Japonés | MEDLINE | ID: mdl-12632606

RESUMEN

We investigated the features and the usefulness of gallium scintigraphy in the diagnosis and the assessment of Adult Still's disease (ASD) by retrospective case review. Gallium scintigraphy have been done for 11 cases of ASD (3 males and 8 females) and 4 females were positive. Among these, 67 Ga-citrate was accumulated to the bone marrow in all 4 cases and to the major joints in 2 cases. Positive cases were rather serious and administered more immunosuppressants than negative cases. In order to characterize gallium scintigraphy findings of ASD, i.e. bone marrow accumulation, we analyzed 130 cases of collagen vascular diseases. Although 101 cases (77.7%) were positive, only 7 cases (5.4%) showed the accumulation of 67Ga-citrate to the bone marrow. These include 3 cases with ASD, and 1 case with systemic lupus erythematosus, polyarteritis nodosa, Wegener's granulomatosis and Sjögren's syndrome. We also accumulated 18 patients who exhibited bone marrow accumulation of 67Ga-citrate, and found that 7 patients had collagen vascular and their related diseases. In conclusion, bone marrow accumulation in gallium scintigraphy is a specific feature of collagen vascular diseases, especially ASD, and it is suggested that cases with positive gallium scintigraphy in ASD can be serious and resistant to treatment.


Asunto(s)
Médula Ósea/diagnóstico por imagen , Médula Ósea/metabolismo , Citratos , Radioisótopos de Galio , Galio , Radiofármacos , Adulto , Anciano , Citratos/farmacocinética , Diagnóstico Diferencial , Femenino , Galio/farmacocinética , Radioisótopos de Galio/farmacocinética , Humanos , Masculino , Persona de Mediana Edad , Cintigrafía , Radiofármacos/farmacocinética , Estudios Retrospectivos , Enfermedad de Still del Adulto
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA